Skip to content
DataLookout
Menu

NCT06911112

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 21 words
    • Trial sites expanded: 39 → 42 locations
    • Interventions modified
    • Study title revised
  2. Minor Trial sites expanded: 10 → 39 locationsv4
  3. Minor Study sites: 1 to 10v3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2025 to Mar 31, 2025
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56
Timeframe: Baseline, Day 56

Secondary (2)

Change from Baseline in Sheehan Disability Scale (SDS) Total Score at Day 56
Change from Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score at Day 56

Arms and interventions

OsavampatorExperimental

Osavampator administered orally once a day.

PlaceboPlacebo comparator

Placebo identical in appearance to osavampator will be administered orally once a day.

Drugs: Osavampator, Placebo

Sites

42 sites in 5 countries

United States 20, Slovakia 7, Bulgaria 6, Lithuania 5, Romania 4